Course Code: BP105T
Unit I Overview
Unit I: Fundamentals of Pharmacognosy. This unit explains how natural materials become recognised drug sources. It connects biological identity, historical discoveries, quality standards and the ways crude drugs are classified.
Topics Covered – Syllabus Coverage
| Required topic | Coverage |
|---|---|
| Definition and core concepts | 1.1 |
| History and development | 1.2 |
| Present status and scope | 1.3 |
| Plant sources | 1.4 |
| Animal, microbial and marine sources | 1.5-1.7 |
| Plant tissue culture | 1.8 |
| Morphine and quinine | 1.9-1.10 |
| Aspirin and warfarin | 1.11-1.12 |
| Penicillin and cephalosporins | 1.13-1.14 |
| Taxol and artemisinin | 1.15-1.16 |
| Pharmacopoeias and monographs | 1.17-1.18 |
| Ayurvedic, Unani and American Herbal Pharmacopoeias | 1.19-1.21 |
| Official and non-official drugs | 1.22 |
| Codified and non-codified drugs | 1.23 |
| Six classification systems: examples, merits and limitations | 1.24-1.29 |
| Quick revision and examination practice | 1.30 |
Learning outcomes
- Define pharmacognosy and explain its development and scope.
- Identify plant, animal, microbial, marine and tissue-culture drug sources.
- Distinguish the source organism, medicinal part, preparation and constituent.
- Explain all eight historical drug-discovery milestones.
- Describe the role of pharmacopoeias and read the structure of a monograph.
- Distinguish official status from traditional codification.
- Compare all six classification systems with examples, merits and limitations.
Essential terms
| Term | Meaning |
|---|---|
| Crude drug | Natural material with limited processing |
| Biological source | Organism and medicinal material used |
| Constituent | Chemical component of the material |
| Marker | Substance used in quality assessment |
| Monograph | Standards for a defined article |
| Authentication | Confirmation of identity and source |
| Chemotype | Chemical variant within a species |
The guiding question: What is the drug’s source, which part is used, what does it contain, and how can its identity and quality be established?
1.1 What is pharmacognosy?
Pharmacognosy is the study of drugs and medicinal substances obtained from natural sources, including their origin, identification, constituents, properties, quality and applications. Modern pharmacognosy also investigates natural-product discovery, biosynthesis, biotechnology and standardisation.
The word combines Greek roots: pharmakon, meaning drug, and gnosis, meaning knowledge. Its central concern is knowledge of a natural drug as a biological material and as a source of useful chemicals.
Crude drug
A crude drug is a natural substance that has undergone relatively limited preparation, such as collection, cleaning, drying or cutting. It may be an identifiable organ, a secretion or another natural material. ‘Crude’ describes the stage of processing; it does not automatically mean poor quality.
| Material | Example and meaning |
|---|---|
| Whole/part drug | Senna leaflets; ginger rhizome |
| Natural exudate | Acacia gum; opium latex |
| Extract | Components removed into a suitable solvent |
| Isolated compound | Morphine; quinine; artemisinin |
Source terminology in an answer
Biological origin: the organism and specified material.
Geographical origin: where the source grows or is produced.
Commercial origin: the place or trade route from which the material reaches the market.
A supplier’s address cannot replace a botanical identity.
Drug, extract and isolated molecule
The crude drug is the collected material. Extraction transfers selected soluble substances into a preparation. Isolation then separates an individual compound. The composition and specification change at each stage; a plant’s name alone does not describe the extract’s strength or its constituent content.
Why identity comes first
Two plants can share a common name but differ in composition. Conversely, one plant may have several regional names. Therefore, botanical identity, medicinal part and origin must accompany the commercial drug name.
A complete biological source
State the accepted scientific name, family and part used. For example: dried flower buds of Syzygium aromaticum, family Myrtaceae, are clove. Merely writing ‘clove plant’ leaves the medicinal material unspecified.
Organised and unorganised drugs
Organised drugs retain recognisable cellular organisation. Leaves, roots, bark, flowers and seeds are typical examples. External form and microscopic tissues help identify them.
Unorganised drugs lack a recognisable organ structure in the collected product. They include gums, resins, latex, oils and waxes. Their source and chemistry are usually more useful than a tissue section of the product.
| Point | Organised | Unorganised |
|---|---|---|
| Examples | Senna, ginger | Acacia, castor oil |
| Identity clues | Organ and tissues | Physical and chemical characters |
| Key caution | Powdering hides form | Absence of tissues is expected |
Crude drug versus active constituent
Senna leaflets contain multiple substances, including sennosides. A leaf drug and purified sennosides are different materials with different specifications. The amount of drug powder cannot be treated as the same amount of a purified compound.
Related fields
- Botany: taxonomy, plant organs and anatomy.
- Phytochemistry: isolation, structure and analysis of plant chemicals.
- Pharmacology: effects, mechanisms and biological activity.
- Pharmaceutics: formulation and delivery of the medicine.
- Ethnopharmacology: scientific investigation of traditional medicinal practices.
Identification is not proof of efficacy
Authenticating a plant answers ‘what is it?’ Assay answers ‘how much of the specified substance is present?’ Biological and clinical evidence address activity and therapeutic benefit. These questions complement one another.
Diagram labels: Leaf tissue; veins; organised: recognisable plant organ; unorganised: collected gum tears.
Recall: Natural source → authentic drug material → characterised preparation → evaluated medicine. Each transition requires evidence.
1.2 Historical development
Natural materials were used therapeutically long before isolated molecules became available. Early knowledge came from observation, experience and transmission through traditional systems. Later developments introduced written descriptions, botanical identification, chemical isolation and experimental testing.
Important periods
| Period / event | Contribution |
|---|---|
| Early traditions | Empirical use of plants, animals and minerals |
| Classical medicine | Written materia medica and preparations |
| Botanical expansion | Descriptions, collections and comparison of species |
| Early 19th century | Isolation of active principles such as morphine |
| 20th century | Antibiotics, analytical methods and industrial production |
| Modern period | Molecular analysis, biotechnology and evidence-based standardisation |
Important contributors
Dioscorides described medicinal materials in De Materia Medica. Galen contributed to preparation of medicinal products; ‘galenical’ preparations are associated with extraction and formulation of natural materials.
Indian traditions preserved medicinal knowledge in works associated with Charaka and Sushruta. Their significance belongs to the development of systematic medical knowledge, rather than the isolation of a single modern molecule.
Naming of the subject
The term pharmacognosy is associated with Johann Adam Schmidt’s 1811 work and C. A. Seydler’s 1815 Analecta Pharmacognostica. Remember both milestones rather than treating the later date as the only historical use.
From materia medica to a science
Earlier materia medica mainly collected descriptions and uses of medicinal substances. Pharmacognosy developed stronger methods for distinguishing species, recognising tissues, detecting substitution and connecting drugs with chemical constituents.
Why isolation changed medicine
Isolation separated a biologically active substance from a variable mixture. This allowed chemical characterisation, more consistent measurement and systematic study. It also revealed that natural materials can contain powerful substances with significant toxicity.
Development of quality assessment
- Stage 1: recognise the material. Observe form, surface, colour and other appropriate characters.
- Stage 2: confirm internal identity. Examine diagnostic tissues or powder features.
- Stage 3: analyse composition. Use characteristic tests, chemical fingerprints and assays.
- Stage 4: connect quality with performance. Evaluate impurities, contaminants, stability and appropriate biological activity.
Discovery is a team process
A named scientist may make the initial observation, while other researchers isolate the compound, determine its structure, establish activity and solve production problems. Drug-history answers should distinguish these contributions.
Development of the discipline: examination outline
- Traditional stage: observation, preparation and transmission of natural-drug knowledge.
- Descriptive stage: written materia medica and recognition of medicinal materials.
- Botanical stage: systematic naming, comparison and authentication.
- Chemical stage: isolation and structure determination of active principles.
- Experimental stage: biological testing and industrial production.
- Modern stage: integrated chemical, molecular and biotechnological investigation with reproducible standards.
These stages overlap; they are a study framework rather than a claim that all regions followed one identical timeline.
Important historical contrasts
- Traditional use can generate a lead; it does not establish a modern indication by itself.
- Isolation gives a defined compound; formulation still affects delivery.
- Laboratory activity suggests a possibility; clinical development evaluates use in people.
- A drug’s discovery date and commercial introduction date are often different.
Memory line: Observe → describe → identify → isolate → evaluate → standardise. This sequence summarises the scientific development of pharmacognosy.
1.3 Present status and scope
Pharmacognosy extends beyond recognition of dried plants. It supports natural-product research, herbal-product quality, pharmaceutical raw materials and sustainable sourcing. It brings together biological identity and chemical analysis.
Major areas of work
| Area | Main question |
|---|---|
| Authentication | Is this the intended species and part? |
| Phytochemistry | Which constituents are present? |
| Quality control | Does the batch meet its specification? |
| Drug discovery | Can a natural product provide a useful lead? |
| Biotechnology | Can cells or microbes produce the substance? |
| Conservation | Can the source be supplied sustainably? |
Pharmaceutical applications
Natural sources supply active drugs, lead molecules, precursors and excipients. Examples include quinine as a plant alkaloid, penicillin as a microbial product, plant-derived precursors for semisynthesis, acacia as a gum and alginates from algae.
Standardisation
Standardisation establishes reproducible identity and quality. A useful specification can combine biological identity, chemical profile, content of suitable markers and limits for contaminants. One marker alone may not describe the entire mixture.
Modern analytical tools
Chromatographic fingerprints compare multiple components. Spectroscopic methods help establish structures. DNA-based methods can support identity when suitable genetic material is present, but do not measure potency or prove absence of chemical adulterants.
Natural products and drug development
A natural molecule may become a drug unchanged, supply a chemical scaffold for modification or provide a starting material for semisynthesis. An herbal preparation may instead remain a characterised mixture; its development requires control of the mixture and manufacturing process.
Industry and professional roles
- Authentication and purchase of medicinal raw materials.
- Development of monographs and analytical methods.
- Production of extracts and natural-product intermediates.
- Investigation of adulteration, contamination and deterioration.
- Research on medicinal plants, microbes and marine organisms.
- Documentation of traditional knowledge with appropriate consent and benefit-sharing.
Supply and conservation
Destructive collection of roots or bark can threaten slow-growing species. Cultivation, responsible collection, use of renewable parts and biotechnology can reduce pressure on wild populations. A useful medicine must have a feasible, reliable supply route.
Challenges in natural-drug work
Species confusion, geographic variation, season, chemotype and processing can change composition. Storage can introduce moisture damage or microbial growth. A visually acceptable sample may still be chemically unsuitable.
A practical example
Two batches labelled ‘senna’ may differ in leaf identity, foreign matter, constituent profile or contamination. The pharmacist needs more than the trade name to decide whether either batch is suitable.
Natural does not define quality: The natural origin of a substance says nothing by itself about dose, purity, safety or therapeutic value. Quality depends on the material and its evidence.
Diagram labels: Authenticate; extract; separate; test activity; characterise; evaluate quality (QC).
1.4 Plants as sources of drugs
Plants supply medicinal organs, secretions, extracts and isolated compounds. The active constituents may be unevenly distributed, so the medicinal part is essential to the biological source.
Reading a medicinal plant
Identify the growth habit, leaf arrangement, venation, flower form and reproductive parts. A botanical illustration of the source plant helps recognise its identity; the commercial drug may contain only the harvested leaf, bark or another organ.
Why part used matters
Leaves and roots from the same species can differ in chemical composition. Substituting one organ for another cannot be justified merely because the plant name is unchanged.
Diagram labels: Tubular corolla; stamens; leaf midrib; reticulate veins.
Important plant-drug examples
| Drug | Source and medicinal part |
|---|---|
| Senna | Senna alexandrina; leaflets and pods |
| Clove | Syzygium aromaticum; dried flower buds |
| Ginger | Zingiber officinale; dried rhizome |
| Liquorice | Glycyrrhiza glabra; roots and stolons |
| Cinnamon | Cinnamomum verum; bark |
| Castor oil | Ricinus communis; fixed oil from seeds |
| Digitalis | Digitalis species; medicinal leaves |
Botanical names
A binomial has a genus and a species epithet, for example Papaver somniferum. The genus begins with a capital letter; the species epithet is lower case. Family names group related genera and normally end in -aceae.
Geographic and commercial origin
Biological source identifies the organism and part. Geographic source describes where it occurs or is produced. Commercial source concerns the region or route from which the marketed drug is supplied. These are related but not interchangeable.
Variation within a plant drug
Climate, soil, age, season and cultivation conditions can change yield and constituent content. A chemotype can show a different chemical profile despite belonging to the same species.
A source profile: clove
Biological source: dried flower buds of Syzygium aromaticum, family Myrtaceae.
Important constituent: eugenol in the volatile oil.
Classification: organised flower-bud drug; volatile-oil-containing drug.
The harvested bud differs from the opened flower and from the mature fruit.
Identification sequence
- Step 1: match the name and medicinal part.
- Step 2: compare whole-drug morphology.
- Step 3: confirm diagnostic microscopic features where applicable.
- Step 4: compare chemical identity and relevant quality tests.
Diagram labels: Flower bud; open flower; leaf veins; stem.
Exam example: Clove is a flower-bud drug, not a leaf drug. Ginger is a rhizome, not a true root. Correct organ terminology prevents common classification errors.
1.5 Animal sources
Animals supply secretions, tissues and biochemical materials. Examples include honey, beeswax, lanolin, gelatin and some pharmaceutical proteins or polysaccharides. A product’s historical source may differ from its present industrial production route.
| Material | Source / pharmaceutical relevance |
|---|---|
| Honey | Honeybees; sugar-rich natural product |
| Beeswax | Honeybee secretion; formulation material |
| Lanolin | Purified wool grease; topical excipient |
| Gelatin | Collagen-derived material; capsule shells |
| Heparin | Animal tissue source; anticoagulant material |
Historical versus current production
Insulin was historically extracted from animal pancreases. Much present-day insulin is produced by recombinant microorganisms. In an answer, distinguish the original natural source from current biotechnology.
1.6 Microbial sources
Fungi and bacteria produce antibiotics and other useful metabolites. Penicillium species supply penicillins; Streptomyces species produce several antibiotic families. Microorganisms also serve as hosts for recombinant products.
Industrial importance
A producing strain is grown under controlled conditions. Nutrient composition, aeration, temperature and culture time affect production. The useful substance must then be separated and purified; a culture broth is not automatically a finished drug.
1.7 Marine sources
Marine algae, sponges, tunicates, microorganisms and other organisms supply pharmacologically interesting compounds. The marine environment supports unusual structures and biological interactions that can generate useful drug leads.
| Example | Source / significance |
|---|---|
| Agar | Red algae; gelling and culture-medium material |
| Alginates | Brown algae; thickening and pharmaceutical applications |
| Carrageenan | Red algae; polysaccharide material |
| Ziconotide lead | Cone-snail peptide; inspiration for a synthetic drug |
| Cytarabine history | Nucleoside leads from marine sponge research |
A source does not always remain the factory
An original marine compound may be supplied commercially by synthesis, fermentation or another controlled route. Sustainable production is especially important when an organism is rare or difficult to collect.
Diagram labels: Forked blade; thallus; holdfast; stipe.
Endophytes and symbiotic microbes
Microorganisms living within plants or associated with marine organisms may produce bioactive chemicals. The apparent host organism and the actual producer can therefore differ. Establishing the producer requires experimental evidence.
Comparing source categories
Plant-source identification emphasises taxonomy and medicinal part. Animal products require source traceability and suitable processing. Microbial products require strain and process control. Marine leads require identity, chemistry and an acceptable supply route.
Remember: Plant, animal, microbial and marine describe source categories. They do not automatically describe a compound’s chemical class or therapeutic action.
1.8 Plant tissue culture
Plant tissue culture is the growth of plant cells, tissues or organs on a suitable nutrient medium under controlled aseptic conditions. It can support propagation, conservation and production of selected metabolites.
Essential terms
- Explant: tissue used to initiate culture.
- Callus: proliferating, relatively undifferentiated tissue.
- Cell suspension: dispersed cells or small aggregates grown in liquid medium.
- Organ culture: maintenance of organised roots, shoots or other organs.
Basic sequence
- Step 1: select authenticated material. Choose a suitable healthy donor and explant.
- Step 2: establish asepsis. Surface-disinfect the explant and use sterile equipment and medium.
- Step 3: initiate culture. Provide mineral nutrients, a carbon source and suitable growth regulators.
- Step 4: maintain or differentiate. Conditions may favour callus, roots or shoots depending on the objective.
- Step 5: evaluate the product. Measure growth, identity, metabolite profile and reproducibility.
- Step 6: scale appropriately. Cell cultures can enter controlled production; regenerated plantlets require acclimatisation.
Diagram labels: Explant; callus; shoots; rooted plantlet; agar medium; then acclimatise plantlet.
Advantages
- Selected material can be multiplied under controlled conditions.
- Production need not depend entirely on seasonal wild collection.
- Rare germplasm can be maintained for conservation programmes.
- Cell or root cultures can be investigated for metabolite production.
Limitations
- Sterile establishment and maintenance require skill and equipment.
- Contamination can destroy a culture.
- A fast-growing culture may produce little of the desired metabolite.
- Genetic or epigenetic changes may alter the profile.
- Large-scale production requires economic and quality evaluation.
Organised cultures and metabolite production
Micropropagation aims to regenerate plantlets. Cell-suspension culture aims to grow cells in liquid medium and may be investigated for metabolite production. Hairy-root culture uses transformed roots with a characteristic growth pattern. These are different culture systems; a callus does not automatically develop into a useful metabolite-producing factory.
Selection of a productive line, control of growth conditions and repeated chemical analysis help determine whether production is reliable. A growth regulator ratio may influence organogenesis, but responses depend on species, explant and medium.
Pharmacognostic example
Taxus cell culture can produce paclitaxel. This illustrates how a plant-derived drug can be manufactured without repeatedly removing bark from wild trees. Culture production still requires a controlled cell line, process and purification.
Discovery-to-product map
Authenticate source → prepare extracts → screen activity → fractionate → identify active substances → evaluate → solve supply and formulation → establish quality.
Steps often need repeating; the path is not always linear.
Bioassay-guided fractionation
An extract is separated into fractions. Each fraction is tested in an appropriate assay. Activity guides further separation until candidate substances are characterised. Activity may involve several components rather than one compound.
What this approach cannot establish alone
A laboratory assay does not establish an effective human dose. An isolated compound can lose the mixture’s apparent activity, and a positive assay can reflect non-specific toxicity. Relevant follow-up evaluation is necessary.
1.9 Morphine
Natural source: opium, the dried latex obtained from unripe capsules of Papaver somniferum, family Papaveraceae.
Chemical class: alkaloid.
Significance: a major early example of isolating a defined active principle from a crude drug.
Diagram labels: Flower petals; drooping bud; ripe capsule; lobed leaf.
Discovery milestone
Friedrich Wilhelm Adam Sertürner isolated and investigated morphine in the early nineteenth century; 1805 is a commonly used teaching milestone. His work helped establish that a plant drug’s effect could be associated with an isolatable chemical substance.
Historical lesson
Opium is a complex natural mixture, while morphine is a defined constituent. The discovery transformed the way researchers connected a crude drug with its activity and measured amount.
1.10 Quinine
Natural source: bark of Cinchona species, family Rubiaceae.
Chemical class: quinoline alkaloid.
Historical application: antimalarial activity associated with cinchona bark.
Pierre-Joseph Pelletier and Joseph-Bienaimé Caventou isolated quinine in 1820. Isolation provided a chemically defined substance for study and more reproducible preparations than variable bark material.
Why these discoveries matter together
Morphine and quinine showed that powerful activities of medicinal plants could be connected with distinct chemicals. They stimulated alkaloid chemistry and the separation of active principles from biological mixtures.
| Point | Morphine | Quinine |
|---|---|---|
| Source drug | Opium latex | Cinchona bark |
| Family | Papaveraceae | Rubiaceae |
| Class | Alkaloids in both cases | Alkaloids in both cases |
| Milestone | Sertürner | Pelletier and Caventou |
| Key idea | Active-principle isolation | Active-principle isolation |
Remember the contributor
Sertürner was a German pharmacist whose work on morphine helped develop the concept of a chemically defined active principle. His importance lies in the experimental isolation and investigation, rather than in merely naming the opium plant.
Distinction: Morphine is not the botanical source of opium. Quinine is not another name for cinchona bark. Separate source material, constituent and discovery contributor.
Diagram labels: Tubular flowers; opposite leaves; stem; midrib.
Cinchona identity
The source is a tree with opposite leaves. The medicinal crude drug is bark, not the flowers shown on the source-plant branch. Bark contains a mixture of alkaloids; quinine is one constituent.
1.11 Aspirin
Willow and other plants helped establish medicinal interest in salicylate chemistry. Aspirin is acetylsalicylic acid, a manufactured derivative of salicylic acid; it is not simply powdered willow bark.
Work at Bayer associated with Felix Hoffmann in 1897 produced material suitable for development; aspirin was introduced in 1899. Earlier acetylation chemistry preceded this industrial milestone.
Aspirin: significance
The story illustrates natural lead → chemical modification → pharmaceutical product. The salicylate lead came from natural-product knowledge, but the finished compound and production process differed from the traditional plant preparation.
Acetylation principle
Salicylic acid + acetic anhydride → acetylsalicylic acid + acetic acid.
Acetylation changes the phenolic hydroxyl group. This equation describes a chemical transformation, not a complete manufacturing procedure.
Diagram labels: Salicylic acid (C7H6O3); acetic anhydride; phenolic OH is acetylated; acetylsalicylic acid (C9H8O4); acetic acid is formed as a coproduct.
1.12 Warfarin
The discovery route began with haemorrhagic disease in cattle fed spoiled sweet-clover hay. Investigations identified dicoumarol, an anticoagulant formed in spoiled material. Karl Paul Link and colleagues developed related compounds; warfarin is a synthetic derivative, not the constituent directly extracted from hay.
Key milestones
- Spoiled sweet-clover disease supplied the original observation.
- Dicoumarol linked the disease with a defined anticoagulant.
- Development of related compounds led to warfarin.
- Warfarin entered rodenticide use in 1948.
- Warfarin sodium entered human therapeutic use in 1954.
Why the example belongs here
Warfarin demonstrates that an unwanted biological effect can lead to a useful drug when the responsible chemistry is understood and modified. Natural origin of a lead does not require the final medicine to remain a natural extract.
Common examination error: Write dicoumarol from spoiled sweet clover; warfarin developed as an analogue. Do not call warfarin the naturally occurring chemical discovered in spoiled hay.
1.13 Penicillin
Source category: microbial, from Penicillium moulds.
Chemical family: beta-lactam antibiotics.
Initial milestone: Alexander Fleming’s 1928 observation of bacterial growth inhibition near a mould contaminant.
Observation to medicine
Fleming recognised the inhibitory phenomenon. Later work by Howard Florey, Ernst Chain and their team, including important process contributions, established purification, experimental treatment and clinical development. Industrial fermentation made large-scale supply possible.
Significance
The story connects an accidental observation with systematic microbiology, chemistry and manufacturing. Observation alone did not create a stable, available medicine.
Diagram labels: Conidia; phialides; stalk; septum; mould colony; inhibited zone; susceptible bacteria grow outside the zone.
1.14 Cephalosporins
Giuseppe Brotzu investigated a fungus from a sewage-contaminated marine environment near Sardinia in 1945. The organism was historically called Cephalosporium acremonium and is commonly associated with Acremonium chrysogenum in later terminology.
Subsequent work isolated and characterised cephalosporin C and established the beta-lactam framework that supported semisynthetic cephalosporin development. Cephalosporin C was an important starting point rather than a complete substitute for all later cephalosporin medicines.
Natural versus semisynthetic antibiotics
A naturally produced compound may have limitations in activity, stability or delivery. Modifying a suitable nucleus can generate related medicines with altered properties. The source organism and the final semisynthetic drug should be named separately.
| Point | Penicillin | Cephalosporin |
|---|---|---|
| Initial contributor | Fleming | Brotzu |
| Milestone | 1928 | 1945 |
| Source category | Fungal in both cases | Fungal in both cases |
| Shared chemistry | Beta-lactam family | Beta-lactam family |
| Development | Isolation, evaluation and production | Isolation, evaluation and production |
Basic fermentation sequence
- Step 1: establish a suitable producing strain.
- Step 2: grow the inoculum and production culture under controlled conditions.
- Step 3: monitor the process and product formation.
- Step 4: separate, purify and evaluate the product.
Recall distinction: An antibiotic-producing mould is a source organism. Its broth contains nutrients, cells and other metabolites. Purified antibiotic and formulated medicine are later stages of development.
1.15 Taxol / paclitaxel
Original source: bark of the Pacific yew, Taxus brevifolia, family Taxaceae.
Chemical class: taxane diterpenoid.
Development milestone: isolation and structural work reported by Monroe E. Wall, Mansukh C. Wani and colleagues in 1971.
Discovery significance
Screening of natural materials led to an important anticancer lead. Subsequent research showed its action on microtubules and addressed difficult questions of supply, formulation and development.
Conservation and supply
Harvesting bark from slow-growing trees can damage or kill them. Semisynthetic routes using suitable precursors and plant-cell culture helped develop more sustainable supply. The original source does not necessarily identify the current manufacturing route.
Diagram labels: Flat needle leaf; exposed seed; woody branch; fleshy aril.
1.16 Artemisinin
Natural source: Artemisia annua, family Asteraceae, especially its aerial parts.
Class: sesquiterpene lactone with an endoperoxide group.
Major milestone: isolation of artemisinin in 1972, following antimalarial research during Project 523.
Tu Youyou and collaborating researchers connected traditional knowledge with extraction and experimental testing. Lower-temperature extraction was an important improvement in obtaining active material.
Artemisinin: development lesson
Traditional use suggested a lead. Researchers then changed extraction conditions, tested activity and characterised the active substance. The useful scientific lesson is that the preparation method affects the chemical product.
Diagram labels: Flower heads; divided leaf; stem; roots.
Artemisinin derivatives subsequently became important in antimalarial medicine. Their pharmaceutical use differs from taking an unstandardised plant preparation; the history of a discovery should not be confused with instructions for treatment.
Eight discoveries: quick comparison
| Drug | Key source or lead |
|---|---|
| Morphine | Opium latex; alkaloid isolation |
| Quinine | Cinchona bark; alkaloid isolation |
| Aspirin | Salicylate knowledge; acetylation |
| Warfarin | Dicoumarol lead; synthetic analogue |
| Penicillin | Penicillium; microbial metabolite |
| Cephalosporins | Fungal cephalosporin C; derivatives |
| Paclitaxel | Taxus bark; taxane discovery |
| Artemisinin | Artemisia annua; antimalarial lead |
Four discovery patterns
- Isolation: morphine and quinine.
- Modification of a lead: aspirin and warfarin.
- Microbial discovery: penicillin and cephalosporins.
- Screening/traditional knowledge plus development: paclitaxel and artemisinin.
Answer-writing example
For paclitaxel, state source and class, identify Wall and Wani’s contribution, explain anticancer discovery significance, and mention supply development. Naming the tree alone does not explain the milestone.
Recall: M-Q / A-W / P-C / T-A groups the eight required drugs into four pairs for revision.
1.17 Pharmacopoeial standards
A pharmacopoeia is a compendium of standards for medicinal substances and products. Its monographs describe identity, quality requirements and appropriate tests. Status and applicability depend on the jurisdiction and relevant requirements.
What a herbal monograph may contain
| Element | Purpose |
|---|---|
| Definition | Specifies material, source and part |
| Identification | Confirms intended article |
| Macroscopy / microscopy | Describes diagnostic characters |
| Chemical identification | Characteristic tests or fingerprint |
| Purity tests | Controls foreign matter and impurities |
| Assay / marker content | Measures specified constituents |
| Storage / labelling | Supports continued quality and traceability |
General chapters
A monograph is read together with applicable general notices and test methods. The full standard may therefore include instructions outside the individual drug entry.
A monograph is not a treatment manual
Pharmacopoeial compliance establishes defined quality requirements. It does not by itself prove effectiveness for every claimed indication, nor does it supply an individual patient’s treatment plan.
Batch versus name
A correctly named plant can fail a purity or assay limit. Compliance is assessed for the actual article or batch, not inferred merely from a supplier’s label.
The complete standard considers:
- Species, part and form of the article.
- External characters, tissues and chemical profile.
- Foreign matter and relevant contamination tests.
- Specified constituent or marker assay.
- Storage, labelling and applicable general notices.
Diagram labels: Definition: species, part and form of the article. Identification: external characters, tissues and chemical profile. Purity: foreign matter and relevant contamination tests. Content: specified constituent or marker assay. Handling: storage, labelling and applicable general notices.
1.18 Major compendia
Indian Pharmacopoeia (IP): published by the Indian Pharmacopoeia Commission. It provides standards for drugs and includes herbal materials and products within its coverage.
British Pharmacopoeia (BP): a standards compendium used in the United Kingdom. It includes relevant herbal-drug and preparation standards together with general methods and notices.
United States Pharmacopeia-National Formulary (USP-NF): provides recognised standards for covered articles. USP also develops standards relevant to dietary supplements and herbal ingredients.
Herbal medicines and dietary supplements
The syllabus phrase ‘USP – Herbal Medicines and Dietary Supplements’ concerns USP’s standards activity in these areas. It should not imply that every herbal supplement is an approved drug or that every herbal article has the same regulatory category.
Choosing the right standard
- Step 1: identify the article precisely.
- Step 2: determine applicable jurisdiction and product category.
- Step 3: locate the appropriate monograph and general chapters.
- Step 4: apply the complete specification using suitable validated methods.
- Step 5: document compliance and deviations for the actual batch.
Why editions matter
Names, methods and requirements may be revised. Learn the role of each compendium rather than memorising an edition-dependent number as a universal rule.
Memory line: Definition → identity → purity → content → storage. These are the main questions answered by a quality monograph.
1.19 Ayurvedic Pharmacopoeia of India
The Ayurvedic Pharmacopoeia of India (API) establishes standards for covered Ayurvedic materials and formulations. It connects traditional names with identifiable materials and modern quality requirements.
Typical entries describe the botanical source, part used, diagnostic characters and suitable tests. Standards help separate authentic material from substitutions sold under a similar regional name.
Pharmacopoeia versus formulary
A pharmacopoeia emphasises quality standards. A formulary provides formulation-related information such as ingredients and preparation of recognised formulations. They serve related purposes but are not interchangeable terms.
1.20 Unani Pharmacopoeia of India
The Unani Pharmacopoeia of India (UPI) supplies standards for covered Unani drugs and preparations. It supports identity and quality while retaining the terminology needed to connect the material with the traditional system.
Indian institutional context
The Pharmacopoeia Commission for Indian Medicine & Homoeopathy, under the Ministry of AYUSH, is associated with development of standards for these systems. The IP and the API are different compendia with different scopes; their abbreviations should not be confused.
1.21 American Herbal Pharmacopoeia
The American Herbal Pharmacopoeia (AHP) develops herbal monographs addressing identity and quality, with therapeutic information associated with its work. It is distinct from USP and should not be described as automatically having the same official legal standing as a national statutory pharmacopoeia.
Why specialised herbal standards help
Herbal materials are complex and variable. Their identity may depend on botanical characters, microscopy and chemical profiles together. A standard for a single synthetic compound cannot simply be copied for an entire plant mixture.
| Compendium | Main focus |
|---|---|
| IP | Standards for covered medicinal articles in India |
| BP | British standards and applicable methods |
| USP-NF / related USP standards | Quality standards for covered articles |
| API | Ayurvedic drugs and formulations |
| UPI | Unani drugs and formulations |
| AHP | Herbal identity/quality monographs |
How a traditional monograph supports identity
A regional drug name may refer to several plants. The monograph’s source definition fixes which organism and part belong to the article. Macroscopic characters describe the supplied material, microscopy supplies tissue evidence, and chemical methods add constituent evidence. No single line in the entry should be treated as the complete quality specification.
Example: shared plant, different preparation
A plant may appear in more than one tradition. Each preparation may use a different part, extraction process or combination. The quality definition must match the actual material; a monograph for the raw herb is not automatically the complete specification for a finished extract.
Common examination errors
- Calling API and IP the same book.
- Treating a formulary as an identity test.
- Assuming a quality monograph approves all therapeutic claims.
- Assigning all compendia identical legal status.
Recall: Identify the publisher/scope, article covered and purpose. These distinguish the compendia more reliably than their titles alone.
1.22 Official and non-official drugs
An official drug is included in the relevant recognised pharmacopoeia or official compendium for the context being considered. A non-official drug is not included in that specified compendium.
The classification is relative to the compendium, jurisdiction and edition. It is not a permanent global property of a plant. State the context before giving examples or making comparisons.
What official status means
An entry supplies a recognised standard for the covered article. The actual sample must still be tested; presence of the name in a book does not make every marketed batch compliant.
What non-official does not mean
Absence from a selected pharmacopoeia does not automatically establish that a drug is useless or prohibited. It may require another justified specification and appropriate evidence for its intended category and claims.
| Question | Correct distinction |
|---|---|
| Is it listed? | Official status in specified compendium |
| Does this sample pass? | Batch compliance with specification |
| Is the source authentic? | Identity/authentication |
| Does the use have evidence? | Therapeutic evaluation |
Illustrative test
If a plant drug is listed in the compendium named in an examination question, classify it as official in that context. If it is absent, classify it as non-official there; do not infer a worldwide status.
1.23 Codified and non-codified drugs
Codified drugs have their medicinal use recorded within recognised authoritative literature of an established traditional system.
Non-codified drugs are associated with local, folk or oral practices without that form of recognised textual codification in the context considered.
Separate two questions
Official status asks whether an article is included in the relevant official compendium. Codification asks whether its traditional use is documented within authoritative system literature. A drug can be discussed under both axes.
Examples of contexts
Classical Ayurvedic or Unani texts represent codified traditions. A locally transmitted tribal remedy may represent a non-codified practice until its knowledge is systematically documented within an appropriate recognised framework.
Why the distinction matters
Codified literature can help identify names, parts, preparations and traditional rationale. Non-codified knowledge can also generate useful leads. Both still require authentication, quality assessment and suitable evaluation for modern products.
Four-way comparison
| Basis | Main concern |
|---|---|
| Official / non-official | Inclusion in specified recognised compendium |
| Codified / non-codified | Authoritative written traditional documentation |
Documentation and ethics
Record the local name, botanical identity, part and preparation without assuming that a vernacular name identifies one species. Respect community knowledge, consent and benefit-sharing during research.
Common error: Codified is not a synonym for official. Neither term alone demonstrates a batch’s purity or proves a therapeutic claim.
1.24 Alphabetical classification
Drugs are arranged by their names in alphabetical order, using a consistent naming convention. The scheme is common in indexes, catalogues and reference organisation.
Example
Acacia → Belladonna → Cinchona → Digitalis → Ginger → Senna.
This order says where to find an entry; it does not describe chemical relationships or therapeutic similarity.
Merits
- Simple to use when the name is known.
- Convenient for dictionaries, stock lists and indexes.
- Easy to add another entry without rebuilding biological groups.
- Works with drugs from different source categories.
Limitations
- Related drugs can appear far apart.
- Synonyms and regional names can cause duplicate entries.
- Does not indicate part, constituents or action.
- An unknown specimen cannot be identified by alphabetical order alone.
1.25 Morphological classification
Drugs are grouped by the form or organ of the collected material: leaves, roots, rhizomes, bark, flowers, fruits, seeds, whole herbs, or unorganised products.
Merits
Useful for whole-drug recognition and pharmacognostic study. It connects the commercial sample with external and microscopic characters. Students can compare similar organs side by side.
Morphological groups and examples
| Group | Typical example |
|---|---|
| Leaf | Senna; digitalis |
| Root / stolon | Liquorice |
| Rhizome | Ginger |
| Bark | Cinnamon; cinchona |
| Flower bud | Clove |
| Fruit | Fennel |
| Seed | Ispaghula |
| Whole aerial herb | Some herb drugs |
| Gum | Acacia |
| Latex | Opium |
| Fixed oil | Castor oil |
Diagram labels: Shoot base; scale scars; rhizome; adventitious roots. A rhizome is stem tissue, not a root.
Limitations
The scheme does not directly show chemistry or action. Several unrelated plants have similar organs. Powdering can remove useful external clues. Extracts and highly processed products may no longer resemble their source organs.
Organ terminology
A root is usually a non-node-bearing underground organ. A rhizome is an underground stem with nodes and buds. A bark drug is obtained from tissues outside the vascular cambium. A flower bud is an immature flower, not a fruit.
Exam comparison
Ginger belongs to the rhizome group; its pungent constituents also permit chemical grouping. Cinchona belongs to the bark group and to the alkaloid group. Classification depends on the chosen basis.
Recall: Morphology answers ‘what part or form is supplied?’ It does not answer ‘what compound is present?’
1.26 Taxonomical classification
Drugs are organised according to the biological relationships of their source organisms. Plant drugs may be grouped by family, genus and species within a taxonomic hierarchy.
Hierarchy
Kingdom → division → class → order → family → genus → species.
Contemporary systems may use clades and revise traditional placements; the central principle is biological relationship.
Representative families
| Family | Medicinal examples |
|---|---|
| Solanaceae | Belladonna; Datura |
| Apiaceae | Fennel; coriander |
| Fabaceae | Senna; liquorice |
| Asteraceae | Artemisia; chamomile |
| Rubiaceae | Cinchona |
| Myrtaceae | Clove |
Merits
- Connects drug identity with botanical relationships.
- Supports systematic identification and comparative study.
- Helps investigate related species as possible research leads.
Diagram labels: Kingdom Plantae; family Myrtaceae; genus Syzygium; species Syzygium aromaticum; drug material: dried flower buds, clove. Selected levels shown; intermediate ranks omitted.
Limitations
Closely related species may differ substantially in constituents or toxicity. A botanical family does not guarantee one action. Classification changes and synonyms require care. Unorganised products still need their biological source traced before placement.
1.27 Chemical classification
Drugs are grouped by their characteristic or important constituents, such as alkaloids, glycosides, volatile oils, tannins, resins, carbohydrates or lipids.
| Chemical group | Drug example |
|---|---|
| Alkaloids | Cinchona; opium |
| Anthraquinone glycosides | Senna |
| Cardiac glycosides | Digitalis |
| Volatile oils | Clove; fennel |
| Tannins | Catechu |
| Carbohydrate polymers | Acacia; agar |
| Fixed oils | Castor oil |
Merits
Connects pharmacognosy with phytochemistry. It helps organise extraction, separation and analytical approaches. Drugs containing related compounds can be compared even when their plants are unrelated.
Limitations
A crude drug contains several chemical groups. Different authors may choose different dominant constituents for placement. Drugs with unknown chemistry cannot be assigned confidently. Similar chemistry need not imply an identical therapeutic action.
Important chemical contrasts
Fixed oils consist mainly of lipid components and do not behave like volatile oils, which contain volatile constituents. Alkaloids are a chemical grouping; antimalarial is an action grouping. Senna’s morphology is a leaflet or pod, not ‘a glycoside’.
Constituents can span several groups
Liquorice contains glycosides and other constituents; clove contains volatile oil as well as non-volatile components. Placement in one chemical group usually highlights the constituents most important for the study purpose. It does not imply that every other chemical class is absent.
Worked example: clove
Morphological group: flower bud.
Taxonomical group: Myrtaceae.
Chemical group: volatile-oil-containing drug, with eugenol as an important constituent.
These descriptions complement one another.
1.28 Pharmacological classification
Drugs are grouped according to their predominant biological or therapeutic action, for example laxatives, carminatives, antimalarials or cardiotonic drugs.
| Action group | Typical teaching example |
|---|---|
| Laxative | Senna; ispaghula |
| Carminative | Fennel |
| Antimalarial lead | Cinchona; Artemisia annua |
| Cardiac glycoside source | Digitalis |
| Anticancer-drug source | Taxus |
Merits
- Convenient for connecting natural drugs with therapeutic applications.
- Groups different source organisms by a useful biological question.
- Helps recall the relevance of a constituent or preparation.
Limitations
A drug can have more than one action. Different preparations may act differently. An action label can hide major chemical differences. Laboratory activity is not equivalent to an established clinical indication.
Compare two laxative types
Senna supplies stimulant-laxative constituents, whereas ispaghula is a bulk-forming material. A shared broad action group does not mean their composition and mechanisms are identical.
Example of multiple placement
Cinchona is a bark drug morphologically, a Rubiaceae drug taxonomically, an alkaloid drug chemically and an antimalarial source pharmacologically.
1.29 Chemotaxonomical classification
Chemotaxonomy uses chemical characters to investigate and support relationships among organisms. Characteristic compounds or biosynthetic patterns are considered together with botanical evidence.
Principle
Related organisms may share biosynthetic pathways and characteristic metabolites. A chemical pattern can therefore support identification or relationship studies. It is supporting evidence, not a rule that every member of a family has the same composition.
A simple chemotaxonomic investigation
- Step 1: authenticate related species and preserve voucher material.
- Step 2: sample comparable organs at comparable stages.
- Step 3: use the same extraction and analytical method.
- Step 4: compare characteristic chemical profiles with the botanical relationships.
- Step 5: check alternative explanations such as season, chemotype or analytical sensitivity.
A reproducible pattern may support a relationship. A single similar peak cannot, by itself, establish that two plants belong to the same family.
Teaching examples
Tropane alkaloids are useful chemical characters in certain Solanaceae genera. Glucosinolate patterns are important in Brassicaceae. Essential-oil patterns can help compare members of some aromatic plant groups.
Merits
- Adds chemical evidence to taxonomic study.
- Helps investigate related species and possible natural-product leads.
- Can distinguish chemically different populations or chemotypes.
- Connects biological relationship with biosynthetic research.
Limitations
Environment, age and processing may alter detected profiles. Similar compounds can occur in unrelated taxa. Absence may reflect the method or tissue sampled. Reliable interpretation needs authenticated specimens and suitable analysis.
Chemical versus chemotaxonomical
Chemical classification groups drugs because they contain a selected constituent class. Chemotaxonomy uses chemical features to study relationships of source organisms. The objectives are different even when the same compounds are measured.
Recall: Taxonomy: related organisms. Chemistry: related constituents. Chemotaxonomy: chemical evidence for organism relationships.
Comparable peaks may suggest shared chemical characters. Interpret them together with authenticated botanical identity.
Diagram labels: Matched sample A; matched sample B; signal; retention time. Comparable peaks may suggest shared chemical characters, interpreted with authenticated botanical identity.
1.30 Compare the six systems
| System | Main basis | Limitation |
|---|---|---|
| Alphabetical | Name | Gives no biological relationship |
| Morphological | Organ or form | Chemistry is not shown |
| Taxonomical | Source relationships | Action can differ |
| Chemical | Constituents | Mixtures fit several groups |
| Pharmacological | Action | Mechanisms can differ |
| Chemotaxonomical | Chemistry and taxonomy | Profiles can vary |
Solved classification: senna
Source: Senna alexandrina.
Morphology: leaflets or pods.
Family: Fabaceae.
Chemistry: anthraquinone glycosides, including sennosides.
Pharmacology: stimulant-laxative source.
Alphabetical placement depends on its chosen entry name.
Solved classification: acacia
Product: gum from appropriate Acacia/Senegalia source species as defined for the article.
Morphology: unorganised gum.
Chemistry: carbohydrate-rich polysaccharide material.
Its biological source remains essential despite the product lacking a recognisable leaf or root structure.
Quick distinction checklist
- Ginger: rhizome, not root.
- Clove: flower bud, not fruit.
- Opium: latex mixture; morphine: constituent.
- Cinchona: bark; quinine: alkaloid.
- Dicoumarol: spoiled-clover compound; warfarin: analogue.
- Codified: textual tradition; official: compendial inclusion.
- Taxus bark discovery: distinct from modern production route.
Long-answer questions
- Define pharmacognosy. Discuss its history, present status and scope.
- Explain natural sources of drugs with suitable examples, including tissue culture.
- Describe the eight drug-discovery milestones in the syllabus.
- Compare the major pharmacopoeias and herbal/traditional compendia.
- Discuss the six classification systems with examples, merits and limitations.
Short-answer questions
- Differentiate organised and unorganised drugs.
- Distinguish a crude drug, an extract and an isolated compound.
- What is a biological source? Give one complete example.
- Explain official versus non-official status.
- Distinguish codified from non-codified drugs.
- Compare chemical classification and chemotaxonomy.
- Why did paclitaxel development create a supply problem?
- How did penicillin move from observation to industrial medicine?
Self-check with answers
Which group contains ginger? Rhizomes.
Who isolated quinine in 1820? Pelletier and Caventou.
What does a monograph primarily establish? Identity and quality standards for its defined article.
Does one family imply one action? No; biological relationship and pharmacological action are separate bases.
A strong answer
Define the basis, organise examples in a table, explain advantages, then identify the limitations. Include the correct organ and distinguish the plant source from its constituent.
Final recall
Identity → source → constituents → quality → application.
Use these five questions to connect every topic in this unit.